Skip to main content

Table 1 Correlations between EIF5A2 expression and clinicopathologic characteristics of EOC patients

From: EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis

Characteristics All cases EIF5A2 protein P value
Low expression High expression
Age (years, mean) 76 57 55 0.28
Histological type     0.201
 Serous 61 25 (41.0%) 36 (59.0%)  
 Others 15 9 (60.0%) 6 (40.0%)  
Histological grade     0.724
 Well/moderate 10 5 (50.0%) 5 (50.0%)  
 Poorly 66 29 (43.9%) 37 (56.1%)  
Lymphatic metastasis     0.108
 No 63 30 (47.6%) 33 (52.4%)  
 Yes 13 4 (30.8%) 9 (69.2%)  
FIGO stage     0.263
 IIIc 58 28 (48.3%) 30 (51.7%)  
 IV 18 6 (33.3%) 12 (66.7%)  
Residual disease     0.381
 ≤ 10 mm 59 28 (47.5%) 31 (52.5%)  
 > 10 mm 17 6 (35.3%) 11 (64.7%)  
Clinical response     0.039
 Complete 68 33 (48.5%) 35 (51.5%)  
 Partial 7 1 (14.3%) 6 (85.7%)  
 Non-response 1 0 (0.0%) 1 (100.0%)  
Platinum sensitivity     0.014
 Sensitive 60 31 (51.7%) 29 (48.3%)  
 Resistant* 16 3 (18.8%) 13 (81.2%)  
  1. *Platinum-resistant was defined as those with relapse within 6 months after primary chemotherapy or progress during the primary chemotherapy